Cambridge Antibody Technology co-founder and CEO, Dr Chiswell brings 30 years of biotechnology experience to IGEM’s Board London, 9 April 2019 – IGEM Therapeutics (IGEM),
Appointment brings significant commercial pharma experience as Enterprise Therapeutics’ two lead respiratory programmes are progressed towards the clinic Brighton, UK: Enterprise Therapeutics Ltd (Enterprise), a
No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process CRESTWOOD, Ky. and WALTHAM,
Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains
Edinburgh, Scotland, 28th February, 2019 – AdoRx Therapeutics, a UK based drug discovery company, today announced that it has entered into a strategic collaboration with
New designation now includes all PNH patients CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development
CRESTWOOD, Ky., and WALTHAM, Mass., – Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases
Represents New Hope for Repairing Challenging Bone Fractures Aberdeen, UK, January 31, 2019– SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes to transform the
New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE therapeutic antibody portfolio and novel
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom, 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular